发明申请
US20110257891A1 THERAPY PREDICTION AND OPTIMIZATION FOR RENAL FAILURE BLOOD THERAPY, ESPECIALLY HOME HEMODIALYSIS
有权
治疗失败血液治疗的治疗预防和优化，特别是家庭心脏病学
- 专利标题： THERAPY PREDICTION AND OPTIMIZATION FOR RENAL FAILURE BLOOD THERAPY, ESPECIALLY HOME HEMODIALYSIS
- 专利标题（中）： 治疗失败血液治疗的治疗预防和优化，特别是家庭心脏病学
-
申请号： US13088044申请日： 2011-04-15
-
公开(公告)号： US20110257891A1公开(公告)日： 2011-10-20
- 发明人: Alp Akonur , John Kenneth Leypoldt , Ying-Cheng Lo , Baris Ugar Agar
- 申请人： Alp Akonur , John Kenneth Leypoldt , Ying-Cheng Lo , Baris Ugar Agar
- 申请人地址： CH Glattpark (Opfikon) US IL Deerfield
- 专利权人： BAXTER HEALTHCARE S.A.,BAXTER INTERNATIONAL INC.
- 当前专利权人： BAXTER HEALTHCARE S.A.,BAXTER INTERNATIONAL INC.
- 当前专利权人地址： CH Glattpark (Opfikon) US IL Deerfield
- 主分类号： G06F19/00
- IPC分类号： G06F19/00
摘要：
A method of predicting serum phosphorus concentrations in a patient during hemodialysis includes measuring serum phosphorus concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a phosphorous mobilization clearance and a pre-dialysis distribution volume of phosphorus for the patient. Serum phosphorus concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated phosphorous mobilization clearance and pre-dialysis distribution volume of phosphorus of the patient.
公开/授权文献
信息查询
